Category: Regulatory Affairs
Formatting, hyperlinking, and validation issues surface late in eCTD compilation, forcing rework at the worst possible time.
Assembling a submission into a compliant electronic dossier is exacting work: granular document placement, hyperlinking, bookmarks, and technical validation rules that vary by agency. Problems found late — broken links, misplaced documents, validation failures — force rework in the days before a filing date. AI-assisted publishing tools automate formatting and checking so issues surface while there is still time to fix them calmly.
Publishing automation works on the mechanical layer of a submission: placing documents correctly in the eCTD structure, generating and verifying hyperlinks and bookmarks, checking granularity and lifecycle operations, and validating the package against agency technical rules before it ships. Automated checking finds the broken link or misplaced document in minutes, continuously, rather than in a manual QC pass that happens late because the content kept changing. The result is that technical findings arrive while documents are still being finalized, not in the final week. Publishing specialists still control the submission structure and make the judgment calls on placement and lifecycle; the automation removes the repetitive checking and formatting from their workload and keeps the package continuously close to valid as content evolves.
Validation coverage is the substance behind the demo: which agencies' technical rules the tool checks, how quickly it incorporates rule changes, and how its findings compare with the gateway validators your submissions must ultimately pass. Ask for specifics by region — coverage that is strong for one agency may be shallow elsewhere — and test against a past submission whose issues you already know. Then consider workflow: whether checking runs continuously as documents change or only on demand, how findings route to the people who can fix them, and how the tool coexists with your document management and regulatory information systems. As with all regulated tooling, examine audit trails and validation documentation for the tool itself.
A revealing pilot is running the tool against a recently filed submission and comparing its findings with the issues the team actually caught — and any that slipped through to the agency gateway. That calibrates the tool's coverage against known ground truth without touching a live filing. Teams then typically adopt continuous checking on the next submission's working documents, well before the compilation crunch.
It automates the mechanical layer — document placement, hyperlinking, bookmarks, and validation against agency technical rules — and checks continuously as content changes, so problems surface early instead of in a late manual QC pass. Publishing specialists keep control of structure and judgment calls.
Because manual technical QC traditionally waits for near-final content, and content is final only near the deadline. Broken links and validation failures are then discovered exactly when there is least time to fix them. Continuous automated checking breaks that coupling by validating the package as it evolves.
No. Specialists own the submission structure, lifecycle strategy, and the judgment calls automated rules cannot make. The automation removes repetitive checking and formatting from their workload — which matters most during the pre-filing crunch when their attention is the scarcest resource.
Ask which agencies' validation rules are covered and how quickly rule changes are incorporated, how the tool's findings compare with agency gateway validators, whether checking runs continuously or on demand, and how it integrates with your document management system. Testing against a past submission with known issues is the most honest evaluation.
The U.S. FDA renewed and expanded its long-standing collaboration licensing Certara's Simcyp physiologically-based pharmacokinetic (PBPK) simulator, with hundreds of agency licenses used to inform regulatory review of drug dosing and interactions.
Vendor: Certara · press release (Certara (GlobeNewswire)) · 2021-12-21 — Partner: U.S. FDA
Yseop announced a strategic investment and a milestone of clinical trials supported by its generative AI for regulatory and medical writing.
Vendor: Yseop · press release (Yseop (GlobeNewswire)) · 2023-12-07